(Il Sole 24 Ore Radiocor) - Milano, 9 giu - The UK pharmaceutical company GSK said it has reached an agreement to buy Nuvalent, a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies, for 10.6 billion dollars.

Under the terms of the merger agreement, GSK will commence a tender offer to acquire all of Nuvalent's outstanding shares of Class A and Class B common stock at a purchase price of 124 dollars per share in cash within 10 business days. The consideration represents a 40% premium to the last closing price and a 26% premium to the 30 calendar day volume-weighted average price (VWAP).

Net of cash acquired, GSK's aggregate investment is estimated to be 9.4 billion dollars, or 7.1 billion pounds.

The acquisition is consistent with GSK's strategy of acquiring assets that have validated targets and meaningfully address efficacy and/or tolerability limitations of existing standard-of-care therapies. It includes three products in lung cancer in a single transaction.

Zidesamtinib (NVL-520) and neladalkib (NVL-655) are two late-stage, potential best-in-class, next-generation, highly selective ROS1 and ALK inhibitors for treatment of NSCLC.

Both assets have received FDA Breakthrough Therapy and Orphan Drug Designations*and are in review with target decision dates of 18 September 2026 for zidesamtinib and 27 November 2026 for neladalkib. Subject to FDA approval, they are expected to launch in 2026 and have multi-blockbuster potential.

The third asset, NVL-330, is a potential best-in-class HER2 inhibitor currently in phase I trials for HER2-altered NSCLC.

The acquisition also includes Nuvalent's preclinical portfolio of multiple programmes.

GSK said there was no no change to its 2026 full-year guidance range of 7-9% core operating profit and core EPS growth. The acquisition is expected to contribute to revenue growth from 2027, be incremental to the group's existing ambition for sales of over 40 billion pounds by 2031, and to strengthen core operating profit through the dolutegravir loss of exclusivity period (2028-2030).

GSK expects accretion to core operating profit in 2027 and core EPS in 2029 inclusive of synergies and reprioritisation.

Assuming the transaction closes in the third quarter of 2026, GSK expects low single-digit percentage dilution to core EPS for the current year, FY 2027 and FY 2028.

The transaction will be funded primarily from new and existing debt facilities plus cash, with no impact expected to GSK's credit rating.

GSK remains committed to its 70 pence expected dividend for.

2026 and to its progressive dividend policy thereafter.

(RADIOCOR) 09-06-26 09:00:28 (0184) 5 NNNN